Actuate Therapeutics Inc
NASDAQ Global MarketTotal Valuation
Actuate Therapeutics Inc carries a market capitalization of 14.38M, placing it among publicly traded companies globally.
| Market Cap | 14.38M |
| Enterprise Value | N/A |
Share Statistics
Actuate Therapeutics Inc currently has 24.01M shares outstanding.
| Shares Outstanding | 24.01M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 37.14 |
| P/TBV Ratio | 37.14 |
| P/FCF Ratio | -1.77 |
| P/OCF Ratio | -1.77 |
Financial Position
Actuate Therapeutics Inc maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.25 |
| Quick Ratio | 1.16 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,025.85 |
Financial Efficiency
| Return on Equity (ROE) | -849.79 |
| Return on Assets (ROA) | -336.18 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Actuate Therapeutics Inc's stock has declined approximately -91.89445% over the past 52 weeks. The 50-day moving average sits at 1.00, while the 200-day moving average is 2.41.
| Beta (5Y) | N/A |
| 52-Week Price Change | -91.89445% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 2.41 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -20.77M, while operating income came in at -20.77M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -20.77M |
| Pretax Income | -20.45M |
| Net Income | -20.45M |
| EBITDA | -20.77M |
| EBIT | -20.77M |
| Earnings Per Share (EPS) | -0.89 |
Balance Sheet
Total book value stands at 989,152.00, with working capital of 942,745.00 providing operational flexibility.
| Cash & Cash Equivalents | 4.43M |
| Total Debt | N/A |
| Net Debt | -4.43M |
| Equity (Book Value) | 989,152.00 |
| Book Value Per Share | 0.04 |
| Working Capital | 942,745.00 |
Cash Flow
Actuate Therapeutics Inc produced -19.84M in operating cash flow over the past twelve months.
| Operating Cash Flow | -19.84M |
| Capital Expenditures | N/A |
| Free Cash Flow | -19.84M |
| FCF Per Share | -0.86 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -48.36 |
| FCF Yield | -56.53 |
Scores
Actuate Therapeutics Inc posts an Altman Z-Score of -52.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -52.19 |